ADX vs. IBB, HTGC, DNP, PTY, USA, RVT, GSBD, TY, GAB, and STEW
Should you be buying Adams Diversified Equity Fund stock or one of its competitors? The main competitors of Adams Diversified Equity Fund include iShares Biotechnology ETF (IBB), Hercules Capital (HTGC), DNP Select Income Fund (DNP), PIMCO Corporate & Income Opportunity Fund (PTY), Liberty All-Star Equity Fund (USA), Royce Value Trust (RVT), Goldman Sachs BDC (GSBD), Tri-Continental (TY), The Gabelli Equity Trust (GAB), and SRH Total Return Fund (STEW). These companies are all part of the "investment offices, not elsewhere classified" industry.
iShares Biotechnology ETF (NASDAQ:IBB) and Adams Diversified Equity Fund (NYSE:ADX) are both mid-cap finance companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, dividends, profitability, media sentiment, valuation, institutional ownership, analyst recommendations, community ranking and earnings.
Given Adams Diversified Equity Fund's higher probable upside, equities research analysts clearly believe iShares Biotechnology ETF is more favorable than Adams Diversified Equity Fund.
iShares Biotechnology ETF received 13 more outperform votes than Adams Diversified Equity Fund when rated by MarketBeat users. Likewise, 67.09% of users gave iShares Biotechnology ETF an outperform vote while only 53.09% of users gave Adams Diversified Equity Fund an outperform vote.
iShares Biotechnology ETF pays an annual dividend of $0.40 per share and has a dividend yield of 0.3%. Adams Diversified Equity Fund pays an annual dividend of $1.30 per share and has a dividend yield of 6.1%.
iShares Biotechnology ETF has a beta of 0.74, suggesting that its share price is 26% less volatile than the S&P 500. Comparatively, Adams Diversified Equity Fund has a beta of 1.02, suggesting that its share price is 2% more volatile than the S&P 500.
62.5% of iShares Biotechnology ETF shares are held by institutional investors. Comparatively, 28.4% of Adams Diversified Equity Fund shares are held by institutional investors. 0.1% of Adams Diversified Equity Fund shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
In the previous week, iShares Biotechnology ETF had 4 more articles in the media than Adams Diversified Equity Fund. MarketBeat recorded 6 mentions for iShares Biotechnology ETF and 2 mentions for Adams Diversified Equity Fund. iShares Biotechnology ETF's average media sentiment score of 1.17 beat Adams Diversified Equity Fund's score of 0.34 indicating that Adams Diversified Equity Fund is being referred to more favorably in the news media.
Summary
iShares Biotechnology ETF beats Adams Diversified Equity Fund on 6 of the 10 factors compared between the two stocks.
Get Adams Diversified Equity Fund News Delivered to You Automatically
Sign up to receive the latest news and ratings for ADX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ADX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Adams Diversified Equity Fund Competitors List
Related Companies and Tools
